Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus cetuximab in RAS wild-type metastatic colorectal cancer refractory to prior anti-EGFR therapy
jRCTs041180156Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and cetuximab in colorectal cancer (CRC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Disease control rate. Started Sep 2017; status: completed.
02
Drugs
trifluridine + tipiracilcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs041180156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180156.